TY - JOUR T1 - Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker JF - Molecular Pharmacology JO - Mol Pharmacol SP - 49 LP - 59 DO - 10.1124/molpharm.120.000079 VL - 99 IS - 1 AU - Christopher A Hinckley AU - Yuri Kuryshev AU - Alissende Sers AU - Alexander Barre AU - Bruno Buisson AU - Himanshu Naik AU - Mihaly Hajos Y1 - 2021/01/01 UR - http://molpharm.aspetjournals.org/content/99/1/49.abstract N2 - Voltage-gated sodium channels (Navs) are promising targets for analgesic and antiepileptic therapies. Although specificity between Nav subtypes may be desirable to target specific neural types, such as nociceptors in pain, many broadly acting Nav inhibitors are clinically beneficial in neuropathic pain and epilepsy. Here, we present the first systematic characterization of vixotrigine, a Nav blocker. Using recombinant systems, we find that vixotrigine potency is enhanced in a voltage- and use-dependent manner, consistent with a state-dependent block of Navs. Furthermore, we find that vixotrigine potently inhibits sodium currents produced by both peripheral and central nervous system Nav subtypes, with use-dependent IC50 values between 1.76 and 5.12 μM. Compared with carbamazepine, vixotrigine shows higher potency and more profound state-dependent inhibition but a similar broad spectrum of action distinct from Nav1.7- and Nav1.8-specific blockers. We find that vixotrigine rapidly inhibits Navs and prolongs recovery from the fast-inactivated state. In native rodent dorsal root ganglion sodium channels, we find that vixotrigine shifts steady-state inactivation curves. Based on these results, we conclude that vixotrigine is a broad-spectrum, state-dependent Nav blocker.SIGNIFICANCE STATEMENT Vixotrigine blocks both peripheral and central voltage-gated sodium channel subtypes. Neurophysiological approaches in recombinant systems and sensory neurons suggest this block is state-dependent. ER -